The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
Mervyn Singer, Clifford S Deutschman, Christopher Warren Seymour...
https://pubmed.ncbi.nlm.nih.gov/26903338/Actively Recruiting
Led by Regione del Veneto - AULSS n. 7 Pedemontana · Updated on 2026-10-07
430
Participants Needed
2
Research Sites
4 weeks
Total Duration
Sepsis affects millions worldwide each year and remains a leading cause of death despite medical advances. Early and effective treatment is crucial, especially managing fluids and blood pressure. This trial evaluates whether a personalized treatment strategy guided by non-invasive hemodynamic monitoring using the NICaS device improves survival compared to the standard fluid therapy recommended by international sepsis guidelines. Participants are randomly assigned to either a usual-care group receiving fluid resuscitation and vasopressors based on standard clinical signs or to a group guided by NICaS monitoring. The NICaS device measures heart and circulation parameters non-invasively, helping tailor fluid and vasopressor therapy. Fluid challenges and repeated assessments every three hours during the first 12 hours guide treatment adjustments in the NICaS group, while the usual-care group follows standard protocols. Participants will be monitored closely during their hospital stay and for 30 days after enrollment. Assessments include vital signs, fluid intake and output, blood tests, organ function scores, and clinical status. Researchers will compare survival rates, organ support needs, vasopressor use, kidney function, fluid balance, and predict patient outcomes using hemodynamic data combined with common scoring systems. The study aims to determine if this approach can lead to faster stabilization and better outcomes for septic patients.
CONDITIONS
Non-invasive Hemodynamic Optimization of Sepsis in Internal Medicine: a Randomized Study Comparing Therapy Guided by Non-invasive Hemodynamic Indices Versus Standard of Care.
M
Massimo Marchetti, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Regione del Veneto - AULSS n. 7 Pedemontana
Lead Sponsor
University Hospital of Pisa
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - During hospital stay
Participants receive either standard fluid and vasopressor therapy guided by clinical signs or treatment guided by non-invasive hemodynamic monitoring using the NICaS device. In the hemodynamic group, fluid challenges and repeated assessments guide therapy adjustments during the first 12 hours.
Assessments every 3 hours for 12 hours in the hemodynamic group; regular clinical assessments in both groups
Duration - 30 days after hospital admission
Participants are monitored for 30 days after enrollment to assess survival, organ support needs, and clinical outcomes.
Periodic assessments during follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Mervyn Singer, Clifford S Deutschman, Christopher Warren Seymour...
https://pubmed.ncbi.nlm.nih.gov/26903338/Florian B Mayr, Sachin Yende, Derek C Angus
https://pubmed.ncbi.nlm.nih.gov/24335434/Carolin Fleischmann-Struzek, Kristina Rudd
https://pubmed.ncbi.nlm.nih.gov/37975898/Laura Evans, Andrew Rhodes, Waleed Alhazzani...
https://pubmed.ncbi.nlm.nih.gov/34599691/C Fleischmann-Struzek, L Mellhammar, N Rose...
https://pubmed.ncbi.nlm.nih.gov/32572531/Michael Bauer, Herwig Gerlach, Tobias Vogelmann...
https://pubmed.ncbi.nlm.nih.gov/32430052/Kristina E Rudd, Sarah Charlotte Johnson, Kareha M Agesa...
https://pubmed.ncbi.nlm.nih.gov/31954465/Meagan S Kingren, Marlene E Starr, Hiroshi Saito
https://pubmed.ncbi.nlm.nih.gov/34210173/Regione del Veneto - AULSS n. 7 Pedemontana
Lead Sponsor
University Hospital of Pisa
Collaborating Sponsor